Remove sales-marketing white-papers
article thumbnail

Sales coaching: preparing for the new reality in pharma

pharmaphorum

COVID-19 has been a catalyst for a huge amount of change across the pharmaceutical industry, acting as an accelerant for progress in its use of digital technology and prompting a reassessment of how the sales function should work. The industry faces the dawn of a new age in sales coaching. This white paper explains how to adjust to it.

Sales 97
article thumbnail

Pharma agency babble

World of DTC Marketing

HEY NOW: If you want a great example of why pharma needs to build expertise in-house and rely less on agencies, read the newest white paper from Intouch Group. About the only thing I agree with is their assessment of sales reps. This white paper, which is nothing more than an agency marketing tool is a bad reflection on Intouch.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Media means business

pharmaphorum

Havas Lynx Group’s 2020 white paper provides a blueprint for pharma brands to inject meaning into their media. Like so many others, the job of the pharma sales rep has been dramatically affected by the outbreak of COVID-19. The latter is the subject of our 2020 white paper, Media Means Business. About the author.

article thumbnail

Content Marketing as a Sales Driver: Unlocking Your Business Potential in the Pharmaceutical Industry

Pharma Marketing Network

Content Marketing as a Sales Driver: Unlocking Your Business Potential in the Pharmaceutical Industry Content marketing is a long-term strategy that can help businesses of all sizes generate leads, increase brand awareness, and drive sales.

Sales 98
article thumbnail

Kite and Daiichi Sankyo update cell therapy licensing agreement

Pharmaceutical Technology

According to the revised deal, Daiichi Sankyo and Kite will transfer the Marketing Authorization for Yescarta to Gilead’s Japan subsidiary, Gilead Sciences K.K., The therapy’s sales and promotion works in Japan following the transfer of marketing authorisation will be carried out by the Kite Cell Therapy Business Unit at Gilead Sciences K.K.

Licensing 305
article thumbnail

Lilly and ProQR to expand genetic medicine development agreement

Pharmaceutical Technology

Eli Lilly and Company has expanded a licencing and partnership agreement with ProQR Therapeutics to discover, develop and market new genetic medicines. The companies entered the initial agreement in September last year. The post Lilly and ProQR to expand genetic medicine development agreement appeared first on Pharmaceutical Technology.

Genetics 328
article thumbnail

Kite and Arcellx enter partnership for multiple myeloma therapy development

Pharmaceutical Technology

The development, clinical trial and marketing expenses for the cell therapy will be shared by the companies while co-commercialising the product and equally splitting profits from the US region. Kite will oversee the marketing of the product outside the US while Arcellx is eligible for royalty payments on sales.